Gastro Esophageal Junction Cancer Completed Phase 2 Trials for Capecitabine (DB01101)

Also known as: Gastroesophageal-junction Cancer / Gastroesophageal Junction Cancer / Gastro-oesophageal Junction Cancer / Gastro-esophageal Junction Cancer / Gastrooesophageal junction cancer / Carcinoma of oesophagus NOS / Carcinoma of oesophagus / Carcinoma of esophagus (disorder) / Carcinoma of esophagus / Oesophageal carcinoma NOS / Oesophageal carcinoma / Esophageal carcinoma NOS / Esophageal carcinoma / Primary malignant neoplasm of esophagus (disorder)

IndicationStatusPhase
DBCOND0106887 (Gastro Esophageal Junction Cancer)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01748773A Study of the Combination of Oxaliplatin, Capecitabine, and Trastuzumab With Chemoradiotherapy in the Adjuvant Setting in Operated Participants With Human Epidermal Growth Factor Receptor-2 Positive (HER2+) Gastric or Gastroesophageal Junction CancerTreatment